Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H1 2019’, provides in depth analysis on Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System and Genetic Disorders under development targeting Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)

- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects

- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Addex Therapeutics Ltd

Bristol-Myers Squibb Co

Eisai Co Ltd

Eli Lilly and Co

Hua Medicine Shanghai Ltd

Johnson & Johnson

Laboratorio Farmaceutico CT Srl

Novartis ...

Addex Therapeutics Ltd

Bristol-Myers Squibb Co

Eisai Co Ltd

Eli Lilly and Co

Hua Medicine Shanghai Ltd

Johnson & Johnson

Laboratorio Farmaceutico CT Srl

Novartis AG

Park Active Molecules

Richter Gedeon Nyrt

Sosei Heptares

Sumitomo Dainippon Pharma Co Ltd

Toray Industries Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Overview

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Bristol-Myers Squibb Co

Eisai Co Ltd

Eli Lilly and Co

Hua Medicine Shanghai Ltd

Johnson & Johnson

Laboratorio Farmaceutico CT Srl

Novartis AG

Park Active Molecules

Richter Gedeon Nyrt

Sosei Heptares

Sumitomo Dainippon Pharma Co Ltd

Toray Industries Inc

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Drug Profiles

alloswitch-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-952048 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-955829 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-984923 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant IR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSR-98776 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GET-73 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0014242 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-46778212 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-2814617 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-12 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize mGlu5 for Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGluR5 for Schizophrenia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR5 for Anxiety – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize MGLUR5 for Anxiety Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0092273 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0431316 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467558 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Dormant Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Discontinued Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Product Development Milestones

Featured News & Press Releases

Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome

Dec 13, 2018: Sosei Heptares starts new clinical development program – First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders

Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia

Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society

Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

Jan 04, 2016: Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial

Aug 14, 2015: Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s Disease

Jul 22, 2015: Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation

Feb 23, 2015: Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation

Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia

Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1

May 01, 2013: Addex's Dipragluant Demonstrates Dose-dependent mGlu5 Receptor Occupancy In Non-human Primate PET Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Addex Therapeutics Ltd, H1 2019

Pipeline by Bristol-Myers Squibb Co, H1 2019

Pipeline by Eisai Co Ltd, H1 2019

Pipeline by Eli Lilly and Co, H1 2019

Pipeline by Hua Medicine Shanghai Ltd, H1 2019

Pipeline by Johnson & Johnson, H1 2019

Pipeline by Laboratorio Farmaceutico CT Srl, H1 2019

Pipeline by Novartis AG, H1 2019

Pipeline by Park Active Molecules, H1 2019

Pipeline by Richter Gedeon Nyrt, H1 2019

Pipeline by Sosei Heptares, H1 2019

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2019

Pipeline by Toray Industries Inc, H1 2019

Dormant Products, H1 2019

Dormant Products, H1 2019 (Contd..1), H1 2019

Dormant Products, H1 2019 (Contd..2), H1 2019

Discontinued Products, H1 2019

Discontinued Products, H1 2019 (Contd..1), H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports